Statistical considerations for the development of biosimilar products
Journal Title: Generics and Biosimilars Initiative Journal - Year 2014, Vol 3, Issue 1
Abstract
As the patents of a growing number of biological medicines have already expired or are due to expire, it has led to an increased interest from both the biopharmaceutical industry and the regulatory agencies in the development and approval of biosimilars. With the high urgency, European Medicines Agency released the first general guideline on similar biological medicinal products in 2005 and specific guidelines for different drug classes subsequently and US Food and Drug Administration issued three draft guidelines in 2012 on biosimilar product development. A synthesized message from these guidance documents is due to the fundamental differences between small molecule drug products and biological products which are made of living cells, the generic versions of biological products are viewed as similar, instead of identical as the innovative drug product. Thus, more stringent requirement is needed to show no clinically meaningful differences between the biosimilar product and the reference product in terms of the safety, purity, and potency. In this article, we will briefly review statistical issues and challenges in development of biosimilars, including criteria for biosimilarity and interchangeability; selection of endpoints and determination of equivalence margins; equivalence versus non-inferiority; bridging and regional effect; and how to quantify totality-of-the-evidence.
Authors and Affiliations
Nan Zhang, Eric Chi
Keywords
Related Articles
- EP ID EP354173
- DOI 10.5639/gabij.2014.0301.007
- Views 151
- Downloads 0
EORTC continues to support the appropriate treatment of adult patients with G-CSF to prevent febrile neutropenia: guideline updates
The European Organisation for Research and Treatment of Cancer (EORTC) has updated its 2006 guideline on the use of granulocyte colony-stimulating factor (G-CSF) for the prevention of febrile neutropenia (FN), a sometime...
What to look forward to in GaBI Journal, 2014, Issue 2
As mentioned previously, non-biological complex drugs (NBCDs) continue to raise important regulatory and practice issues. This issue of the GaBI Journal contains a number of manuscripts dealing with these products and be...
New product-specific bioequivalence guidance
For harmonization of the authorization requirements for specific generic applications within the EU, consistent criteria were drafted for 16 active substances, which are out now for public consultation.
Statistical considerations for the development of biosimilar products
As the patents of a growing number of biological medicines have already expired or are due to expire, it has led to an increased interest from both the biopharmaceutical industry and the regulatory agencies in the develo...
What lessons can be learned from the launch of generic clopidogrel?
Introduction and study objectives: Resource pressures will continue to grow. Consequently, health authorities and health insurance agencies need to take full advantage of the availability of generics in order to continue...